Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5644308 | 0.88 | EPHX1 (0.45) | USP30EPHX1USP2SMN1; SMN2HPGD | |
| SCHEMBL2189808 | 0.84 | PDE4B (0.46) | USP30NR1H2EPHX1DGAT2USP2 | |
| SCHEMBL3608719 | 0.84 | NR1H2 (0.44) | USP30NR1H2EPHX1DGAT2USP2 | |
| SCHEMBL4984187 | 0.84 | USP30 (0.45) | USP30NR1H2EPHX1DGAT2RORC | |
| SCHEMBL4984190 | 0.84 | USP30 (0.45) | USP30NR1H2EPHX1DGAT2RORC | |
| SCHEMBL458367 | 0.84 | PDE4B (0.46) | USP30NR1H2EPHX1DGAT2USP2 | |
| SCHEMBL2192055 | 0.82 | NR1H2 (0.43) | USP30NR1H2EPHX1DGAT2USP2 | |
| SCHEMBL15885465 | 0.82 | EPHX1 (0.46) | USP30NR1H2EPHX1RORCUSP2 | |
| SCHEMBL24098660 | 0.82 | NR1H2 (0.45) | USP30NR1H2EPHX1DGAT2RORC | |
| SCHEMBL13282934 | 0.80 | NR1H2 (0.46) | USP30NR1H2EPHX1USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2315768-B1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2017-08-09 | — | — | EP | disclosed |
| US-8637491-B2 | Thieno-pyridine derivatives as MEK inhibitors | UCB PHARMA S.A. (BE) | 2014-01-28 | — | — | US | disclosed |
| US-20110172191-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172191-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | MAP2K2, MAP2K1, MAP2K3 | USP30 2621/4885NR1H2 3188/4885EPHX1 568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.